Kwangdong Pharma acquires stake in Precision Bio

The company purchases a 29.7% stake in-vitro diagnostic device company for $12 mn

Kwangdong Pharma acquires stake in Precision Bio
Jeong Min Nam 1
2024-07-03 16:53:28 peux@hankyung.com
Bio & Pharma

South Korea's Kwangdong Pharmaceutical announced on Tuesday that it signed a stock purchase agreement to acquire Precision Biosensor Inc., a company specializing in in-vitro diagnostic devices.

Precision Bio manufactures and sells diagnostic devices and cartridges for both human and animal use.

Kwangdong Pharmaceutical stated that it plans to acquire a 29.7% stake in Precision Bio from its largest shareholder, i-SENS Inc., and others. The acquisition amount is 17 billion won ($12.2 million).

Kwangdong Pharmaceutical explained that the purpose of this stock acquisition is to build infrastructure for entering the personalized healthcare business.

Write to Jeong Min Nam at peux@hankyung.com

Kwangdong to sell exclusively three global rare disease drugs

Kwangdong to sell exclusively three global rare disease drugs

Kwangdong Pharmaceutical CEO Choi Seong-won (left) and Head of Global Rare Diseases at the Chiesi Group Giacomo Chiesi South Korean pharmaceutical company Kwangdong Pharmaceutical announced on Monday that it signed an agreement for securing exclusive sales and distribution rights in the domesti

Kwangdong introduces new drug candidate for pediatric myopia

Kwangdong introduces new drug candidate for pediatric myopia

Kwangdong Pharmaceutical CEO Choi Seong-won (left) and Zhaoke CEO Li Xiaoyi South Korean pharmaceutical company Kwangdong Pharmaceutical announced on Monday that it has signed a contract with Hong Kong-based Zhaoke Ophthalmology Ltd. to introduce a new drug candidate for pediatric myopia called

(* comment hide *}